The Drug-Drug Interaction Profile of Presatovir.
This study enrolled 64 healthy subjects to evaluate the effect of cyclosporine, a P-gp, BCRP, and OATP1B1/1B3 inhibitor; rifampin, a strong CYP3A4 and P-gp inducer; efavirenz, a moderate CYP3A4 inducer; and cobicistat, a potent CYP3A inhibitor, on presatovir pharmacokinetics. Presatovir plasma exposures (maximum observed plasma concentration [Cmax ] and area under the plasma concentration-time curve from time 0 extrapolated to infinity [AUCinf ]) were not affected by coadministration of cyclosporine, suggesting presatovir is not a sensitive substrate of P-gp, BCRP, or OATP1B1/1B3. As expected, based on the role of CYP3A in presatovir metabolism, presatovir exposure was increased by cobicistat (122% in AUCinf ), and decreased by rifampin (40.3% in Cmax and 82.5% in AUCinf ) and efavirenz (55.7% in AUCinf ). These data support coadministration of presatovir with inhibitors of P-gp, BCRP, OATP1B1/1B3, or CYP3A, but not with moderate or strong CYP3A4 inducers. Presatovir was well-tolerated with the most common drug-related adverse events of dizziness (n = 12) and somnolence (n = 4) reported during efavirenz treatment. PMID: 29412463 [PubMed - as supplied by publisher]
Ken and Jane Gremling have shared everything since they got married in 1971, just three weeks after they started dating. But they never expected to receive identical breast cancer diagnoses.
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy.
Two biology researchers from Georgia State University describe the racial gap, why it eludes scientists, and what we are learning about how to close the gap.
Publication date: Available online 18 October 2018Source: Stem Cell ReportsAuthor(s): Leonor Lopez Almeida, Michael Sebbagh, François Bertucci, Pascal Finetti, Julien Wicinski, Sylvie Marchetto, Rémy Castellano, Emmanuelle Josselin, Emmanuelle Charafe-Jauffret, Christophe Ginestier, Jean-Paul Borg, Marie-Josée SantoniSummaryTumor initiation, progression, and therapeutic resistance have been proposed to originate from a subset of tumor cells, cancer stem cells (CSCs). However, the current understanding of the mechanisms involved in their self-renewal and tumor initiation capacity remains limited. Here, ...
Condition: Breast Cancer Intervention: Behavioral: Lifestyle alteration Sponsor: Hospices Civils de Lyon Recruiting
Conditions: Breast Cancer; Acute Pain; Anesthesia Interventions: Procedure: PVB group; Procedure: MTP block group; Procedure: Control Group Sponsor: Ottawa Hospital Research Institute Not yet recruiting
Condition: Breast Cancer Intervention: Drug: Caelyx® Sponsors: European Institute of Oncology; Janssen-Cilag International NV Recruiting
Condition: Breast Cancer Intervention: Device: Macrodyne LivMD plate Sponsor: Indiana University Not yet recruiting
More than 55,000 women in the UK are diagnosed with breast cancer each year, which equates to a staggering 1 in 8 women being diagnosed at some stage... The post Our Macclesfield office holds a Pink Party in aid of breast cancer appeared first on Ashfield Healthcare.
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 -- (Healthcare Sales &Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for... Biopharmaceuticals, Generics, Oncology, Regulatory Mylan, Biocon, Ogivri, Herceptin, trastuzumab, breast cancer, biosimilar